⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15654286 | 1.00 | — | — | |
| SCHEMBL1954837 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2790061 | 0.98 | GRM2 (0.41) | — | |
| SCHEMBL14647435 | 0.82 | — | — | |
| SCHEMBL3294258 | 0.82 | — | — | |
| SCHEMBL8245300 | 0.82 | — | — | |
| SCHEMBL31285696 | 0.82 | — | — | |
| SCHEMBL16240415 | 0.82 | — | — | |
| SCHEMBL8274144 | 0.82 | — | — | |
| SCHEMBL594504 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2624826-B1 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| EP-2417108-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-9206232-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-9011833-B2 | Vitamin E formulations of sulfamide NS3 inhibitors | NOVARTIS AG (CH) | 2015-04-21 | — | — | US | disclosed |
| US-8927484-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140357551-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8840878-B2 | Peptidomimetic sulfamide compounds and antiviral uses thereof | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| US-8613914-B2 | Peptidomimetic sulfamide compounds and antiviral uses thereof | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-8512690-B2 | Derivatised proline containing peptide compounds as protease inhibitors | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2624826-A1 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS | Novartis AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| EP-2625167-A1 | SALTS AND POLYMORPHS OF SULFAMIDE NS3 INHIBITORS | Novartis AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190229-A1 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-07-25 | — | — | US | disclosed |
| US-20130034519-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130022572-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-01-24 | — | — | US | disclosed |
| WO-2012045280-A1 | SALTS AND POLYMORPHS OF SULFAMIDE NS3 INHIBITORS | NOVARTIS AG (CH) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012048235-A1 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS | NOVARTIS AG (CH) | 2012-04-12 | — | — | WO | disclosed |
| WO-2010116248-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260709-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |